Compare Fox Corp Class B (FOX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Regeneron Pharmaceuticals Inc — how do they compare? Fox Corp Class B trades at $56.88 (market cap $24.97B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.1× Fox Corp Class B's market cap, and Fox Corp Class B pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FOX | REGN | |
|---|---|---|
Market Cap | $24.97B | $76.40B |
Volume | 643,221 | 626,381 |
Sector | Media | Health |
52-Week High | $67.76 | $852.03 |
52-Week Low | $44.39 | $557.73 |
Typical Hold Time | 75 Days | 107 Days |
Enterprise Value | $28.33B | $71.12B |
Dividend Yield | 1.04% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.97, up 2.5% today, with a bearish technical signal but strong fundamentals including a P/E of 14.59 and net income margin of 9.84%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while cash flow improved to $1.03B in 2025. The stock faces resistance near $57 with support at $55.
The outlook is mixed: analyst consensus targets $84.75 (49% upside) with 42% buy ratings, but technical indicators and projected 2026 earnings decline pose risks. Key opportunities include valuation discount and dividend yield; risks involve earnings volatility and competitive pressures in media.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
